Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2025.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt reported Q1 FY26 revenue of ₹738 Cr, marginally down from ₹747 Cr in Q1 FY25. EBITDA rose slightly to ₹101 Cr (from ₹100 Cr), with EBITDA margins improving to 13.7% from 13.4%. The company posted a loss after tax of ₹108 Cr, widened from a ₹16 Cr loss a year ago, mainly due to a ₹97 Cr exceptional charge for goodwill impairment of its US step-down subsidiary Morton Grove Pharmaceuticals, which entered Chapter 7 bankruptcy. India business grew 8% to ₹178 Cr, UK grew 13% to ₹312 Cr, and Ireland grew 11% to ₹50 Cr. The company announced a strategic exit from US generics to focus on its innovative antibiotics and biosimilars pipeline, including Zaynich (NDA filing targeted September 2025 with US FDA) and Miqnaf (launched in India in May 2025).
The headline loss looks alarming but is driven by a one-time goodwill write-off from the US generics exit, not core operations. Underlying EBITDA and margins are stable to improving, and the strategic refocus on high-value innovative drugs could support long-term growth, though near-term profitability remains pressured.